search
Back to results

Perioperative Methadone Compared to Placebo in Elderly Hip Fracture Patients

Primary Purpose

Hip Fractures, Methadone

Status
Not yet recruiting
Phase
Phase 4
Locations
Denmark
Study Type
Interventional
Intervention
Methadone Hydrochloride
Placebo
Sponsored by
University of Southern Denmark
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hip Fractures focused on measuring Hip fractures, Elderly, Fragile, methadone, perioperative, analgesic treatment, pain, verbal rating scale, morphine consumption

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients diagnosed with an acute hip fracture (incurred <24 hours ago) on x-rays in the emergency department (ED) at the university hospital of southern Denmark (SHS). This includes collum femoris fractures, pertrochanteric fractures, and subtrochanteric fractures. Patients must be able to read and understand Danish. Exclusion Criteria: Multiple fractures or multi-trauma patient Previous allergic reactions or hypersensitivity towards methadone hydrochloride or sodium chloride Health conditions preventing treatment: Chronic obstructive pulmonary disease with either past exacerbations or daily symptoms History of acute asthma attacks History of drug-induced eczema Pulmonary hypertension Raised intracranial pressure or recent head injury Pheochromocytoma History of paralytic ileus QT-interval prolongation on electrocardiogram (ECG) Myasthenia gravis Known liver disorder Hypotension (systolic blood pressure <100 mmHg at admission) Acute pancreatitis Severe kidney disease (GFR ≤10) Concurrent administration with MAO inhibitors or within 2 weeks of suspending treatment with these medicinal products Concurrent administration of benzodiazepines Impaired cognitive function e.g. dementia. Patients must be able to give informed consent and be able to ask for rescue analgesics if needed Current opioid addiction or intravenous addiction

Sites / Locations

  • Sygehus Sønderjylland

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Methadone

Placebo

Arm Description

Methadone hydrochloride (0.10 mg/kg) administered intravenously at the induction of anaesthesia

Standard saline solution administered intravenously at the induction of anaesthesia

Outcomes

Primary Outcome Measures

Consumption of daily morphine equivalents 3 days post operatively
All opioids (short-acting and long-acting) will be converted into daily morphine milligram equivalent doses. The amount of opioids used by the patient within the last 24 hours will be registered daily. A minimum amount of 0 mg and a maximum amount of 150 mg can be recorded.
Consumption of daily morphine equivalents 3 months post operatively
The opioid consumption will be registered as a mean daily consumption of both long-acting opioids and rescue medication prescribed in the medication chart and reported by the patient. Different types of opioids will be converted into the daily morphine milligram equivalent dose. Minimum score will be 0 mg and the maximum will be 150 mg.

Secondary Outcome Measures

Postoperative pain assessment with verbal rating scale (VRS)
Patients will be asked to assess pain intensity daily in the hip both at rest and when mobilized. Pain intensity will be evaluated using the verbal rating scale consisting of five choices - 1 (No pain), 2 (Slight pain), 3 (Moderate pain), 4 (Severe pain), and 5 (Unbearable pain).
Time until patient first stands up post-surgery
This will be registered in hours and minutes. The minimum is 0 hours and 0 minutes and the maximum is 72 hours and 0 minutes.
Mobility assessment using the Cumulated Ambulation Score (CAS)
The cumulated ambulation score describes the patient's independence with regard to three activities. The first getting in and out of bed, the second ability to transition from sit-to-stand-to-sit from a chair, and the third is walking ability. Each of these activities is assessed on a three-point scale from 0-2 (0 = Not able to, despite human assistance and verbal cueing, 1 = Able to, with human assistance and/or verbal cueing from one or more persons, 2 = Able to safely, without human assistance or verbal cueing. A CAS score will range from zero (worst) to six (best) and will be measure daily.
Number of patients with post operative nausea or vomiting (PONV)
Postoperative nausea or vomiting (PONV) will be registered binomial as "yes" or "no" once daily
Number of days to discharge after surgery
The number of days from ward admission until discharge. Patients moved to another department are still considered hospitalized. The minimum is 0 days and the maximum is 14 days.
Number of patients requiring an antidote
Administration of an antidote will be registered binomial as "yes" or "no". Indications for the use of an antidote include a respiratory frequency of <10/min with peripheral oxygenation of <94% despite 4 liters of oxygen/minute, clinical signs of opioid overdose e.g. disproportionate drowsiness, or if the orthopaedic resident deems it necessary.
Number of patients with delirium assessed using the Confusion Assessment Method (CAM)
Patients will be monitored using the confusion assessment method for signs of delirium. The method is binomial so that 0 means no signs of delirium and 1 means a patient is delirious.
Number of participants with constipation
Occurrence of constipation during admission will be registered binomial as "yes" or "no". A patient with no bowel movements for ≥2 days is considered constipated.
Postoperative pain assessment with verbal rating scale (VRS)
Patients will be asked to assess pain intensity daily in the hip both at rest and when mobilized. Pain intensity will be evaluated using the verbal rating scale consisting of five choices - 1 (No pain), 2 (Slight pain), 3 (Moderate pain), 4 (Severe pain), and 5 (Unbearable pain).
Quality of life assessed using EQ-5D-5L questionnaire
The questionnaire comprises of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
Patient mobility assessed using the new mobility score (NMS)
New mobility score assesses gait; inside the home, outside the home and whilst shopping. A score of 0-3 points is given for each of these three functions, resulting in a total score between 0-9 points.
Number of persistent side effects
The persistent presence of potential adverse reactions will be registered. This includes disproportional dizziness, vertigo, nausea, vomiting, constipation, and drowsiness.

Full Information

First Posted
October 4, 2023
Last Updated
October 12, 2023
Sponsor
University of Southern Denmark
search

1. Study Identification

Unique Protocol Identification Number
NCT06086171
Brief Title
Perioperative Methadone Compared to Placebo in Elderly Hip Fracture Patients
Official Title
Perioperative Methadone Compared to Placebo in Elderly Hip Fracture Patients
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
November 2023 (Anticipated)
Primary Completion Date
May 2025 (Anticipated)
Study Completion Date
August 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Southern Denmark

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Hip fractures are associated with severe pain and are sustained by the elderly population. Demand for adequate pain relief combined with a low tolerance for analgesic drugs makes the treatment of elderly hip fracture patients difficult. Perioperative methadone could improve the analgesic treatment of these patients. An earlier pilot study showed that 0.10 mg/kg was safe to use. This study further investigates the advantages of methadone. The study's objective is to investigate the analgesic effects of a single dose of methadone given during hip fracture surgery.
Detailed Description
Studies investigating the perioperative use of methadone have shown promising analgesic properties. Our pilot study (EudraCT no.: 2022-001857-22) showed that a dosage of 0.10 mg/kg was safe to use and showed excellent analgesic properties. Sufficient management of acute postoperative pain is important in relation to morbidity, hospital costs, and mortality. About 60% of patients undergoing surgical intervention experience moderate to severe postoperative pain. Thus, sufficient analgesic treatment is crucial in the initial postoperative days, which are considered the most painful phase of recovery. Opioids have conventionally been used as an analgesic treatment in this phase. However, this treatment has been accompanied by side effects and addiction. Methadone shares these side effects, however, as methadone only needs to be administered once, the risk of side effects decreases significantly. This study will investigate the analgesic effects of a single dose of methadone given during hip fracture surgery. The first objective is to investigate the analgesic effect of perioperative methadone compared with a placebo in acute hip fracture surgery. The second objective is to investigate the long-term effects of methadone on continued opioid consumption, pain, and mobility three months after surgery. The null hypothesis is that there is no difference in postoperative pain, opioid consumption, or related side effects if a patient receives a dose of methadone or placebo during the surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hip Fractures, Methadone
Keywords
Hip fractures, Elderly, Fragile, methadone, perioperative, analgesic treatment, pain, verbal rating scale, morphine consumption

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
130 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Methadone
Arm Type
Experimental
Arm Description
Methadone hydrochloride (0.10 mg/kg) administered intravenously at the induction of anaesthesia
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Standard saline solution administered intravenously at the induction of anaesthesia
Intervention Type
Drug
Intervention Name(s)
Methadone Hydrochloride
Other Intervention Name(s)
Methadone
Intervention Description
Methadone hydrochloride (0.10 mg/kg) administered intravenously at the induction of anaesthesia
Intervention Type
Other
Intervention Name(s)
Placebo
Other Intervention Name(s)
Saline
Intervention Description
Saline solution
Primary Outcome Measure Information:
Title
Consumption of daily morphine equivalents 3 days post operatively
Description
All opioids (short-acting and long-acting) will be converted into daily morphine milligram equivalent doses. The amount of opioids used by the patient within the last 24 hours will be registered daily. A minimum amount of 0 mg and a maximum amount of 150 mg can be recorded.
Time Frame
3 days post-surgery
Title
Consumption of daily morphine equivalents 3 months post operatively
Description
The opioid consumption will be registered as a mean daily consumption of both long-acting opioids and rescue medication prescribed in the medication chart and reported by the patient. Different types of opioids will be converted into the daily morphine milligram equivalent dose. Minimum score will be 0 mg and the maximum will be 150 mg.
Time Frame
3 months post-surgery
Secondary Outcome Measure Information:
Title
Postoperative pain assessment with verbal rating scale (VRS)
Description
Patients will be asked to assess pain intensity daily in the hip both at rest and when mobilized. Pain intensity will be evaluated using the verbal rating scale consisting of five choices - 1 (No pain), 2 (Slight pain), 3 (Moderate pain), 4 (Severe pain), and 5 (Unbearable pain).
Time Frame
3 days post-surgery
Title
Time until patient first stands up post-surgery
Description
This will be registered in hours and minutes. The minimum is 0 hours and 0 minutes and the maximum is 72 hours and 0 minutes.
Time Frame
up to 72 hours post-surgery
Title
Mobility assessment using the Cumulated Ambulation Score (CAS)
Description
The cumulated ambulation score describes the patient's independence with regard to three activities. The first getting in and out of bed, the second ability to transition from sit-to-stand-to-sit from a chair, and the third is walking ability. Each of these activities is assessed on a three-point scale from 0-2 (0 = Not able to, despite human assistance and verbal cueing, 1 = Able to, with human assistance and/or verbal cueing from one or more persons, 2 = Able to safely, without human assistance or verbal cueing. A CAS score will range from zero (worst) to six (best) and will be measure daily.
Time Frame
3 days post-surgery
Title
Number of patients with post operative nausea or vomiting (PONV)
Description
Postoperative nausea or vomiting (PONV) will be registered binomial as "yes" or "no" once daily
Time Frame
3 days post-surgery
Title
Number of days to discharge after surgery
Description
The number of days from ward admission until discharge. Patients moved to another department are still considered hospitalized. The minimum is 0 days and the maximum is 14 days.
Time Frame
From admission to the ward to discharge, up to 4 weeks
Title
Number of patients requiring an antidote
Description
Administration of an antidote will be registered binomial as "yes" or "no". Indications for the use of an antidote include a respiratory frequency of <10/min with peripheral oxygenation of <94% despite 4 liters of oxygen/minute, clinical signs of opioid overdose e.g. disproportionate drowsiness, or if the orthopaedic resident deems it necessary.
Time Frame
3 days post-surgery
Title
Number of patients with delirium assessed using the Confusion Assessment Method (CAM)
Description
Patients will be monitored using the confusion assessment method for signs of delirium. The method is binomial so that 0 means no signs of delirium and 1 means a patient is delirious.
Time Frame
3 days post-surgery
Title
Number of participants with constipation
Description
Occurrence of constipation during admission will be registered binomial as "yes" or "no". A patient with no bowel movements for ≥2 days is considered constipated.
Time Frame
3 days post-surgery
Title
Postoperative pain assessment with verbal rating scale (VRS)
Description
Patients will be asked to assess pain intensity daily in the hip both at rest and when mobilized. Pain intensity will be evaluated using the verbal rating scale consisting of five choices - 1 (No pain), 2 (Slight pain), 3 (Moderate pain), 4 (Severe pain), and 5 (Unbearable pain).
Time Frame
3 months post-surgery
Title
Quality of life assessed using EQ-5D-5L questionnaire
Description
The questionnaire comprises of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
Time Frame
3 months post-surgery
Title
Patient mobility assessed using the new mobility score (NMS)
Description
New mobility score assesses gait; inside the home, outside the home and whilst shopping. A score of 0-3 points is given for each of these three functions, resulting in a total score between 0-9 points.
Time Frame
3 months post-surgery
Title
Number of persistent side effects
Description
The persistent presence of potential adverse reactions will be registered. This includes disproportional dizziness, vertigo, nausea, vomiting, constipation, and drowsiness.
Time Frame
3 months post-surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients diagnosed with an acute hip fracture (incurred <24 hours ago) on x-rays in the emergency department (ED) at the university hospital of southern Denmark (SHS). This includes collum femoris fractures, pertrochanteric fractures, and subtrochanteric fractures. Patients must be able to read and understand Danish. Exclusion Criteria: Multiple fractures or multi-trauma patient Previous allergic reactions or hypersensitivity towards methadone hydrochloride or sodium chloride Health conditions preventing treatment: Chronic obstructive pulmonary disease with either past exacerbations or daily symptoms History of acute asthma attacks History of drug-induced eczema Pulmonary hypertension Raised intracranial pressure or recent head injury Pheochromocytoma History of paralytic ileus QT-interval prolongation on electrocardiogram (ECG) Myasthenia gravis Known liver disorder Hypotension (systolic blood pressure <100 mmHg at admission) Acute pancreatitis Severe kidney disease (GFR ≤10) Concurrent administration with MAO inhibitors or within 2 weeks of suspending treatment with these medicinal products Concurrent administration of benzodiazepines Impaired cognitive function e.g. dementia. Patients must be able to give informed consent and be able to ask for rescue analgesics if needed Current opioid addiction or intravenous addiction
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kevin Heebøll Nygaard
Email
Kevin.Heeboll.Nygaard3@rsyd.dk
First Name & Middle Initial & Last Name or Official Title & Degree
Jesper Ougaard Schønnemann
Phone
+ 45 79976170
Email
Jesper.Ougaard.Schoennemann1@rsyd.dk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jesper Ougaard Schønnemann
Organizational Affiliation
Sygehus Sønderjylland (Region Syddanmark)
Official's Role
Study Director
Facility Information:
Facility Name
Sygehus Sønderjylland
City
Aabenraa
State/Province
Southern Denmark
ZIP/Postal Code
6200
Country
Denmark

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Perioperative Methadone Compared to Placebo in Elderly Hip Fracture Patients

We'll reach out to this number within 24 hrs